Recent business news includes a report of Q3 2024 EPS improvement and coverage of the company in an article discussing nuclear stocks with real revenue.

• Scientific Industries, Inc. reported Q3 EPS of $0.11 compared to -$0.31 last year, indicating some improvement in profitability [N1].
• The company was mentioned in an article contrasting nuclear stocks with real revenue versus pre-revenue companies, highlighting its revenue-generating status [N1].

The company’s significant investment in bioprocessing product development and its portfolio of patents support its position in a specialized market segment. The introduction of new products in the VIVID® line and ongoing R&D efforts contribute to product offering enhancements. Strong liquidity ratios as of mid-2026 provide financial flexibility to support operations and development. The company’s direct sales force and distributor network in key geographies support market penetration. The sale of the Genie product line allows management to focus resources on higher-potential segments [S1][S2].

The company has a history of operating losses and an accumulated deficit exceeding $35 million as of end-2025. It is heavily dependent on a single major customer for a significant portion of revenue, which poses concentration risk. The remaining Benchtop Laboratory Equipment segment is not yet profitable. The bioprocessing segment is in a start-up phase with uncertain market acceptance. The company faces intense competition from larger firms with greater resources. Supply chain risks due to reliance on outside suppliers and potential patent challenges could adversely affect operations. Limited public market liquidity and thin trading volume may impact capital raising ability [S1][S2].

Scientific Industries holds patents on its VIVID® automated pill counter and several bioprocessing technologies through its Aquila subsidiary, providing some intellectual property protection. The company’s focus on niche laboratory-scale bioprocessing products with smart sensor integration and software analytics differentiates it from larger competitors. However, the company faces competition from substantially larger firms with greater financial and marketing resources. Its ability to maintain proprietary technology and develop innovative products is critical to sustaining competitive advantage. The company’s established relationships with major customers and distributors also contribute to its market position [S1].

• Customer Concentration Risk: Sales to one major customer accounted for approximately 31% of consolidated net revenues in 2025, creating dependency risk if the relationship changes.
• Financial Resources and Capital Requirements: The company has limited financial resources and may need to raise additional funding to continue product development and commercialization, especially in bioprocessing. Failure to secure funding could delay or reduce operations.
• Competition: The company competes with substantially larger firms with greater financial, production, and marketing resources, which may limit market share and pricing power.
• Supply Chain Risks: Dependence on outside suppliers, including single-source suppliers for some components, exposes the company to risks of shortages, delays, and increased costs.
• Intellectual Property Risks: While the company holds patents, there is no guarantee of competitive advantage or that patents will not be challenged or circumvented, which could impact product sales.
• Market Acceptance of Bioprocessing Products: The bioprocessing segment is in a start-up phase with uncertain market acceptance, which could limit revenue growth and profitability.
• Limited Public Market Liquidity: The company’s common stock is thinly traded on the OTC Bulletin Board, which may impair the ability to raise capital and affect stock price volatility.

• Scientific Industries, Inc. (SCND) is a Delaware corporation incorporated in 1954 engaged in the design, manufacture, and marketing of benchtop laboratory equipment and bioprocessing systems through its wholly-owned subsidiary Scientific Bioprocessing Holdings, Inc. (SBHI) and its subsidiaries Scientific Bioprocessing, Inc. and aquila biolabs GmbH [S1].
• The company operates two main segments: Benchtop Laboratory Equipment (including weighing instruments, pill counters, and scales) and Bioprocessing Systems (products with smart sensors and software analytics) [S1].
• On August 7, 2025, SCND sold its Genie product line (part of Benchtop Laboratory Equipment) to Troemner, LLC for $9.6 million plus earn-out payments, and continues to market and produce scales and pill counters in the Benchtop segment [S1].
• Benchtop Laboratory Equipment products include Torbal® and VIVID® branded balances, scales, force gauges, automated pill counters, and moisture analyzers sold primarily online, direct, and through distributors [S1].
• Bioprocessing Systems products include Cell Growth Quantifier (CGQ), Liquid Injection System (LIS), coaster systems, flow-through cells for pH and DO monitoring, Multi-Parameter Sensor (MPS), and Dissolved Oxygen sensor pills marketed under the DOTS brand [S1].
• The company designs and develops substantially all products in-house, with outside consultants augmenting engineering capabilities. It invests significantly in Bioprocessing Systems product development and to a lesser extent in the VIVID® product line [S1].
• Sales to one major customer, mainly for the VIVID® pill counter, represented 31% of consolidated net revenues in 2025 and 23% in 2024, and 42% and 36% of Benchtop segment sales in those years, respectively [S1].
• The company has facilities in Bohemia and Pearl River, New York for Benchtop operations, a shared office in Pittsburgh, Pennsylvania, and a primary operating facility in Baesweiler, Germany for Bioprocessing Systems [S1].
• SCND holds a patent on the VIVID® automated pill counter expiring in March 2039, and its Aquila subsidiary holds three US patents related to bioprocessing expiring between 2036 and 2038, plus several European and PCT patents and pending applications [S1].
• Foreign sales accounted for approximately 17% of net revenue in 2025, primarily in Asia and Europe, with payments mostly in USD [S1].
• The company does not consider its business materially seasonal and does not have a material backlog, as most products ship within one to two weeks [S1].
• Major competitors for Torbal® products include Ohaus Corporation, A&D Company Ltd., Adam Equipment Co., Ltd., Illinois Tool Works, and Capsa Healthcare; for VIVID® automated pill counters, competitors include Medility Inc. [S1].
• Direct competitors for Bioprocessing Systems include ABER Instruments and PreSens GmbH; indirect competitors include Hamilton Bonaduz AG, optek-Danulat GmbH, Sartorius AG, and Eppendorf SE [S1].
• Research and development expenses were $2,487,700 in 2025 and $2,897,900 in 2024, mostly related to Bioprocessing Systems; R&D expenditures are expected to remain material in 2026 [S1].
• The company’s products do not require FDA or other governmental approval; manufacturing is subject to environmental and safety regulations with no significant compliance cost [S1].
• As of March 31, 2026, the company employed 55 persons, with 21 in Benchtop operations and 34 in Bioprocessing Systems, mostly in Europe [S1].
• The company sold the profitable Genie Division in August 2025 and the remaining Torbal division is not yet profitable; the company incurred net losses of $1,220,400 in 2025 and $6,445,400 in 2024, with an accumulated deficit of $35,150,900 as of December 31, 2025 [S1].
• The company’s ability to raise capital is critical to continue product development and commercialization, especially in the Bioprocessing sector; no committed external funding sources exist [S1].
• The company’s financial snapshot as of June 30, 2026, shows cash and equivalents of $515,400, short-term investments of $5,298,600, current assets of $8,127,000, current liabilities of $1,602,200, a current ratio of 5.07, and a cash ratio of 3.63 [S2].
• Revenue for the quarter ended June 30, 2026 was $1,470,400 with a net loss of $1,233,800 and diluted EPS of -$0.10 [S2].
• The company’s products are used primarily for research by universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, and other industries performing laboratory-scale research [S1].
• The company markets Bioprocessing Systems products through a direct sales force in the US and Germany and a network of 11 distributors, supported by marketing campaigns and research partnerships [S1].
• The company faces risks including dependence on a major customer, competition from larger companies with greater resources, supply chain risks due to reliance on outside suppliers, and the need to maintain and protect intellectual property [S1].
• The company’s common stock is thinly traded on the OTC Bulletin Board with 11,928,599 shares outstanding as of March 27, 2026, with 35% held by the three largest shareholders [S1].
• Recent business news includes a 2024 Q3 EPS report showing EPS of $0.11 compared to -$0.31 last year, indicating some improvement in profitability [N1].